Skip to main content
LOCL logo

LOCL · Local Bounti Corporation · Documents

Track LOCL — free
$0.62 -0.14 (-18.51%) At close · Nov 13 Play latest call Q2 2026 earnings call transcript
Market Cap
$14.50M
Shares
23.38M
Volume · Nov 13 34.43K Avg daily vol (3M) 27.23K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $48.37M up 26.8% 10-K filed Mar 27, 2026 Quarterly report FY2026 Q2 Revenue $13.85M up 14.4% 10-Q filed Aug 12, 2026 Latest results Financial results 8-K filed Aug 12, 2026 Earnings call Q2 2026 earnings call Held Aug 12, 2026
2026
Nov 6
Current report 8-K Events of Nov 4
Stockholders approve U.S. Bounti share issuances

At its November 4, 2026 special meeting, Local Bounti Corporation stockholders approved issuing up to 12,563,309 common shares upon conversion of a convertible note issued to U.S. Bounti, LLC and up to 1,000,000 common shares underlying a warrant issued to U.S. Bounti, LLC.

Shareholder vote results
3 source passages
On November 4, 2026, Local Bounti Corporation (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). the issuance of up to 12,563,309 shares of our common stock, par value $0.0001 per share (the “common stock”), upon the conversion of the convertible note issued to U.S. Bounti, LLC (“U.S. Bounti”) the issuance of up to 1,000,000 shares of common stock underlying the common stock purchase warrant issued to U.S. Bounti Open the document at this passage
Nov 5
Current report 8-K Events of Nov 4
NYSE grants nine-month listing compliance extension

The NYSE granted Local Bounti Corporation a nine-month extension, moving its market capitalization compliance deadline from November 5, 2026 to August 5, 2027. Shares remain listed during the cure period, subject to quarterly NYSE progress reviews.

Other events
3 source passages
On November 4, 2026, the Company received a written notice (the “Extension Notice”) from the NYSE informing the Company that the NYSE had accepted the Company’s October 20, 2026 request for a nine-month extension for the Company to regain compliance with the Minimum Market Capitalization Standard. The Extension Notice extends the November 5, 2026 deadline by an additional nine months to August 5, 2027 (the “Market Capitalization Cure Period”), which is the maximum 18-month period permitted under NYSE rules. The Company’s common stock will continue to be listed and traded on the NYSE during the Market Capitalization Cure Period, subject to the Company’s compliance with other NYSE continued listing standards and continued quarterly review by the NYSE of the Company’s progress with respect to its plan. Open the document at this passage
Nov 4
Investor event
Stockholders approve share issuance and adjournment proposals

Local Bounty stockholders approved both proposals: issuance of certain common shares for NYSE rule compliance and authority to adjourn the meeting if deemed necessary or appropriate.

4 source passages
I am Margaret McCandless, General Counsel and Corporate Secretary of Local Bounty. The first proposal is the approval for purposes of complying with NYSE rules of the issuance of certain shares of our common stock. The second proposal is the approval of the adjournment of this meeting if deemed necessary or appropriate. The Inspector of Elections has submitted a preliminary report showing that stockholders have duly approved both proposals. Open the document at this passage
Sep 21
Proxy statement DEF 14A Meeting Nov 4, 2026
Proxy statement

Local Bounti will ask stockholders on November 4, 2026 to approve issuance of up to 12,563,309 common shares for U.S. Bounti’s convertible note and up to 1,000,000 warrant shares, and to authorize meeting adjournment if votes are insufficient.

Read from the first part of this long document
Sep 10
Proxy statement PRE 14A Meeting Nov 4, 2026
Proxy statement AI summary on its way
Aug 12
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $13.85M ▲ 14.4% Net loss $19.82M Diluted EPS -$0.68
May 15
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $13.34M ▲ 14.9% Net loss $12.72M Diluted EPS -$0.53
Apr 23
Proxy statement DEF 14A Meeting Jun 10, 2026
Proxy statement AI summary on its way
Apr 13
Proxy statement PRE 14A Meeting Jun 10, 2026
Proxy statement AI summary on its way
Mar 27
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $48.37M ▲ 26.8% Net loss $94.38M Diluted EPS -$5.61
2025
Showing 1–50 of 158 documents
Key facts CIK 1840780 CUSIP 53960E205 13F (30d) 27 filings 14 filers Visit website Investor relations